Van­da's PhII da­ta of­fer hope for gas­tro­pare­sis pa­tients who have seen no new treat­ments in decades

As one of the hand­ful of drugs-in-de­vel­op­ment for gas­tro­pare­sis, Van­da Phar­ma­ceu­ti­cals’ $VN­DA tradip­i­tant has set it­self apart for the con­di­tion that af­fects about 6 mil­lion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER